John Mack thinks so:
It could be — as I said before — that all this attention brought on by the lobbying PR snafu is actually helping sales of Gardasil. Or, maybe we haven’t yet seen the negative effects of bad publicity work its way through the sales cycle yet. But Merck seems optimistic.
Related posts:
- Too much Gardasil hype
- Gardasil: A "leap of faith"?
- Going contrarian on Gardasil
- BiDil sales "suck"
- Gardasil: New Hampshire shows how it’s done
- Pharmaceutical sales reps on MySpace
- "Pity the poor pharmaceutical sales rep"
KevinMD.com on Facebook
 
Follow on Twitter  
Subscribe







{ 1 comment }
So it this a good time to buy Merck stock?
Comments on this entry are closed.